Hormone Therapy for Perimenopause: What you need to know

Hormone therapy (HT, also called HRT) is the most effective FDA-approved treatment for the hallmark symptoms of perimenopause: hot flashes, night sweats, and vaginal dryness. It can also meaningfully help with sleep disruption, mood changes, brain fog, and bone loss. Yet it remains one of the most misunderstood treatments in women’s health.

Much of the fear surrounding HRT traces back to a single study, the Women’s Health Initiative (WHI) in 2002, whose initial results were widely misinterpreted and led to a generation of women being denied effective treatment. Many of these persistent myths about hormone therapy continue to influence both patients and providers today. Since then, decades of follow-up research have fundamentally changed our understanding of both the benefits and risks. This article presents that updated evidence clearly.

What Hormone Therapy Actually Is

During perimenopause, your ovaries produce increasingly erratic and declining levels of estrogen and progesterone. Hormone therapy replaces what your body is producing less of. That’s it. The concept is straightforward, even if the details require thoughtful discussion with your clinician.

There are two main components:

• Estrogen: the primary hormone that addresses hot flashes, night sweats, vaginal dryness, bone loss, and many other symptoms. The preferred form is estradiol (bioidentical 17-beta estradiol), which is molecularly identical to what your ovaries produce.
• Progesterone: required for any woman who still has a uterus, to protect the uterine lining from thickening (which unopposed estrogen can cause). The preferred form is micronized progesterone (brand name Prometrium), which is bioidentical and has an added benefit: it has calming, sleep-promoting effects. Many women take it at bedtime specifically for this reason.

Types and Delivery Methods

Estrogen Delivery

• Transdermal patch: Applied to the skin, changed once or twice weekly. Bypasses first-pass liver metabolism, which is associated with a lower risk of blood clots than oral estrogen, according to NAMS. Often preferred for patients at higher cardiovascular risk.
• Topical gel or spray: Applied daily to the skin. Same liver-bypass benefit as patches. Good option for women who find patches irritating.
• Oral tablets: Taken daily. Convenient but passes through the liver, which slightly increases clotting risk. Still safe for most women, but transdermal is preferred when possible.
• Vaginal estrogen: Creams, rings, or inserts that deliver very low-dose estrogen locally. Specifically treats vaginal dryness, painful intercourse, and urinary symptoms. Very low systemic absorption, considered safe even for many women who cannot use systemic HRT.

Progesterone Options

• Micronized progesterone (Prometrium): Oral, bioidentical. Taken at bedtime due to its natural sedative effect. Generally well-tolerated with fewer side effects than synthetic progestins.
• Hormonal IUD (Mirena): Delivers progestogen directly to the uterus. Can serve as the progesterone component of HRT while also providing contraception, which is relevant during perimenopause when pregnancy is still possible.
• Synthetic progestins: Older forms (medroxyprogesterone acetate/Provera) are still used but are associated with more side effects than bioidentical progesterone.

What HRT Can Do

The benefits of hormone therapy when started during the window of opportunity are substantial and well-documented. The North American Menopause Society (NAMS) considers HRT the most effective treatment for vasomotor symptoms and recommends it for symptomatic women within the appropriate window:

• Hot flashes and night sweats: NAMS recognizes HRT as the most effective evidence-based treatment for vasomotor symptoms, reducing frequency and severity by 75–90% in clinical trials.
• Vaginal and urogenital health: Significantly improves vaginal atrophy in approximately 75% of women in clinical studies. Also improves urinary symptoms and may reduce recurrent urinary tract infections.
• Bone health: Randomized trial evidence (WHI, 2002) showed a 30–50% reduction in hip fracture risk in women on combined HRT. NAMS recognizes HRT as one of the interventions that can support bone density during the menopausal transition.
• Sleep: Both estrogen (reducing night sweats) and progesterone (its natural sedative effect) are associated with improved sleep quality.
• Mood and cognition: Estrogen has well-documented effects on serotonin and other neurotransmitters. Many women report improvement in mood stability, anxiety, and brain fog.
• Brain health: Some observational studies suggest a possible link between early HRT initiation and reduced long-term cognitive decline. HRT is not FDA-approved or recommended for the prevention of Alzheimer’s disease, and this remains an active area of research.
• Cardiovascular health: When started early (within the window of opportunity), observational evidence associates HRT with reduced cardiovascular risk, in contrast to the older interpretation of the WHI data.

The Window of Opportunity

This is perhaps the most important concept in modern HRT science. The window of opportunity (also called the timing hypothesis) means that hormone therapy should ideally be started within 10 years of menopause onset or before age 60.

When started during this window, HRT is associated with:

• Cardiovascular benefit (not risk)
• Potential neuroprotective effects
• Maximum bone density preservation
• The best overall risk-benefit ratio

When started well after this window, the risk-benefit calculation shifts, particularly regarding cardiovascular health. As ACOG guidelines on the menopause years note, this does not mean HRT is never appropriate after 60, but the conversation with your clinician should be more nuanced.

The practical implication: don’t wait. If your symptoms are significantly affecting your quality of life and you’re a candidate for HRT, starting during perimenopause (rather than waiting until postmenopause) puts you squarely within the optimal window.

Risks: What the Evidence Actually Shows

Any honest discussion of HRT must address risks. Here is what current evidence shows:

• Breast cancer: The most studied concern. Estrogen-only HRT (for women without a uterus) does not increase breast cancer risk; the WHI actually showed a slight decrease. Combined estrogen + progesterone shows a small increase in risk after 5+ years of use, comparable to the risk increase from drinking one glass of wine daily or being overweight. Using micronized progesterone (instead of synthetic progestins) may carry lower risk, though long-term data is still accumulating.
• Blood clots: Oral estrogen slightly increases clot risk. Transdermal estradiol does not. This is why patches and gels are generally preferred.
• Stroke: Very small increased risk with oral estrogen, primarily in women over 60. Transdermal estradiol at standard doses has not been associated with increased stroke risk.

Who Is HRT For?

Hormone therapy may be a good option if you:

• Have moderate to severe hot flashes or night sweats
• Experience vaginal dryness or painful intercourse
• Are at risk for osteoporosis
• Have significant sleep disruption, mood changes, or brain fog related to perimenopause
• Are under 60 or within 10 years of menopause onset
• Do not have contraindications (breast cancer history, blood clots, etc.)

If you’re unsure, a menopause-trained clinician can help you evaluate your individual risk-benefit profile. This is not a decision you need to make alone, and it is not a decision your doctor should dismiss without a thorough conversation.

Getting Started

If you’re considering HRT, here is what a good initial process looks like:

1. Find a knowledgeable provider. Not all doctors are trained in menopause medicine. Look for NAMS-certified menopause practitioners or clinicians who specialize in perimenopause care.
2. Bring your symptom history. Our free assessment can help you document your symptoms clearly.
3. Discuss delivery methods. Transdermal estradiol + oral micronized progesterone is the combination with the best current safety data.
4. Plan for follow-up. Your clinician should check in after 2-3 months to assess response and adjust dosing if needed.
5. Combine with lifestyle changes. HRT works best as part of a comprehensive approach, not as a standalone solution.